IMARC Group, a leading market research company, has recently releases report titled “Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032”, Offers a comprehensive analysis of the industry, which comprises insights on the oncology based in-vivo CRO market share.
How Big is the Oncology Based In-Vivo CRO Market?
The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032.
Industry Overview of Medical Oncology Based In-Vivo CRO
Oncology is a medical discipline focused on studying, diagnosing, and treating cancer through various techniques. The role of an oncology-based in-vivo CRO includes conducting various activities such as tumor xenograft models, efficacy testing of anti-cancer agents, tumor imaging and monitoring, pharmacokinetic and pharmacodynamic evaluations, and toxicity studies. It provides patients with hormonal therapy, immunotherapy, radiotherapy, and oral therapies to manage and alleviate the adverse effects of cancer. These CROs employ specialized scientific and technical personnel who are experienced in performing tumor implantation or inoculation, administering treatments, and collecting and analyzing data related to cancer research.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample
What are the growth prospects and trends in the oncology based In-vivo CRO industry?
The market is being driven by the increasing global prevalence of cancer, which is a key factor. Furthermore, governments across various countries are making extensive investments in research and development (R&D) endeavors. This, in conjunction with the growing expertise of contract research organizations (CROs) in cancer treatment, is fueling market growth. Additionally, there is a rise in genetic engineering innovations that manipulate DNA and modify organism traits.
This, along with a heightened focus on studying oncogenes to regulate cell proliferation, growth, and differentiation, is positively impacting the market. Moreover, the market is being propelled by the wide availability of medicines and the expanding healthcare industry, leading to increased demand for in-vivo CROs specializing in oncology.
Furthermore, the cost-effectiveness offered by CROs compared to in-house studies presents lucrative growth opportunities for industry investors. Furthermore, the adoption of telehealth and virtual clinical trials in the healthcare industry, aimed at ensuring the safety of cancer patients, is expected to further bolster market growth.
Leading Companies Operating in the Global Oncology Based In-Vivo CRO Industry:
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Crown Bioscience Inc.
- Eurofins Scientific
- Evotec SE
- ICON Plc
- Labcorp Drug Development (Laboratory Corporation of America Holdings)
- Living Tumor Laboratory
- Taconic Biosciences Inc.
- The Jackson Laboratory
- WuXi AppTec
- Xentech
Oncology Based In-Vivo CRO Market Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Indication:
- Blood Cancer
- Solid Tumors
- Others
Breakup by Model:
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Others
Breakup by Application:
- Hospitals
- Rehabilitation Centers
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163